Among 920 patients included, KRAS mutations were found in 80 patients (24.5%), with 39 patients found to have co-occurring mutations in STK11 and/or KEAP1. The addition of ICI improved mOS and PFS in the KRAS mutant patients regardless of STK11 and KEAP1 status (Table 7), supporting the use of this regimen in KRAS mutant NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.